Impact of sorafenib on epidural fibrosis: An immunohistochemical study

doi:10.12998/wjcc.v6.i9.249

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6119)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

379

WORD

214

HTML

2762

Figures (1-4)

337

Tables (1-3)

259

Sum=3951

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

878

Download

1290

Sum=2168

Sep 6, 2018 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Clin Cases. Sep 6, 2018; 6(9): 249-258
Published online Sep 6, 2018. doi: 10.12998/wjcc.v6.i9.249

Full Size Figure Download Figure

Figure 1 Fibrosis development mechanism and the stage at which sorafenib prevents fibrosis is indicated. VEGF: Vascular endothelial growth factor.

Citation: Tanriverdi O, Erdogan U, Tanik C, Yilmaz I, Gunaldi O, Adilay HU, Arslanhan A, Eseoglu M. Impact of sorafenib on epidural fibrosis: An immunohistochemical study. World J Clin Cases 2018; 6(9): 249-258
URL: https://www.wjgnet.com/2307-8960/full/v6/i9/249.htm
DOI: https://dx.doi.org/10.12998/wjcc.v6.i9.249